TP53 mutation rates are higher in HER2-positive and TNBC (also referred to as basal-like subtype) compared to luminal-type breast cancer, which are predominantly ER-positive tumors [13,50,51,52,53,54,55,56]. This evidence concerns the gene ERBB2 and breast cancer.